Minimally invasive bone forming product ALLOB in Phase I/IIa trial for delayed union fracture

Bone Therapeutics, the regenerative therapy company addressing unmet medical needs in the field of bone diseases and orthopaedics, announced that the first patient has been treated with its novel allogeneic osteoblastic (bone-forming) cell therapy product ALLOB in its phase I/IIa study for the treatment of delayed union fractures.

ALLOB is the first ever allogeneic differentiated osteoblastic cell therapy product developed for the treatment of orthopaedic conditions. Allogeneic cell therapy involves the harvesting of cells from a healthy, universal donor, rather than from the patient being treated. ALLOB has shown safety and efficacy in preclinical studies and does not require any immunosuppressive side therapy.

ALLOB has the potential to become a first-line treatment for impaired fracture healing, thanks to its minimally invasive percutaneous administration. Delayed union fractures, defined by the absence of fracture healing after three months, affect around 600,000 to 900,000 new patients a year in Europe and the US. The current standard of care for delayed union fractures involves highly invasive surgery, which takes up to several hours followed by a long hospitalisation. ALLOB is injected by the orthopaedic surgeon in a single dose percutaneously, directly into the fracture site. No side-effects have yet been reported.

This first-in-human, proof-of-concept, six months open-label phase I/IIa study is evaluating the safety and efficacy of ALLOB in the treatment of delayed union fractures of long bones. ALLOB treated patients will be assessed in comparison to baseline at two weeks, one, three and six months using clinical (e.g., pain, weight-bearing) and radiological evaluation. Ultimately, 32 patients with delayed union fractures will be enrolled in the study.

Enrico Bastianelli, Chief Executive Officer, Bone Therapeutics commented, “Treating a patient for the first time with our allogeneic product ALLOB is a significant step forward for the progression of Bone Therapeutics’ regenerative therapy pipeline. Our allogeneic approach will lead to an ‘off-the-shelf’ approach to treatment whilst offering delayed union patients the potential for a significant improvement in their condition without the need for invasive surgery. This first in human trial is an important milestone both for realising benefits for the patients as well as creating value for the company.”

EP News Bureau – Mumbai